Fig 1: Nasal and Sinus Mucosa, Related to Figures 4 and 5(A). Expression of ACE2 and TMPRSS2 across donors.(B). Enhanced capture of ACE2 mRNA with second strand synthesis protocol employed in Seq-Well S3. Dot size represents fraction of cells expressing.(C). Cultured human primary basal epithelial cells at confluence were treated with increasing doses (0.1 to 10ng/mL) of IFNa2, IFN?, IL-4, IL-13, IL-17A, and IL-1B for 12 h and bulk RNA-seq analysis was performed (Replicate experiment using Human Donor 1 as in Figure 5)(D). ACE2 expression by stimulation condition. Wilcoxon test between each cytokine (combined doses) versus rest: IFNa Bonferroni-adjusted p = 4.1E-07; IFN? Bonferroni-adjusted p = 9.3E-03; all else n.s. *** p < 0.001.(E). ACE2 expression by IFNa2 dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: *** p < 0.001, * p < 0.05.(F). ACE2 expression by IFN? dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: *** p < 0.001, * p < 0.05.(G). IFITM1 expression by IFNa2 dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: *** p < 0.001.(H). IFITM1 expression by IFN? dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: *** p < 0.001.(I). GBP5 expression among cultured human primary basal epithelial cells. Wilcoxon test: IFNa versus IFN? Bonferroni-adjusted p = 2.94E-07; IFN? Bonferroni-adjusted p = 9.3E-03. TP10K: transcripts per 10,000 reads. *** p < 0.001.(J). GBP5 expression by IFNa2 dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: *** p < 0.001.(K). GBP5 expression by IFN? dose. Bonferroni-corrected t-test compared to 0 ng/mL condition: *** p < 0.001.